FindTrial
Sign In

Reliability Study of Xpert MTB/RIF Detection for Rifampicin Resistance

Reliability Study of Xpert MTB/RIF Detection for Rifampicin Resistance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104669
Enrollment
Unknown
Registered
2025-06-20
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary tuberculosis

Interventions

Gold Standard:phenotypic drug susceptibility testing for Mycobacterium tuberculosis
Index test:Genexpert MTB/RIF

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who tested positive for Mycobacterium tuberculosis culture and Xpert MTB/RIF in our hospital from 2016 to 2023

Exclusion criteria

Exclusion criteria: Exclude patients diagnosed with non tuberculous mycobacterial infection

Design outcomes

Primary

MeasureTime frame
Whether Mycobacterium tuberculosis with different bacterial counts is resistant to rifampicin;—

Countries

China

Contacts

Public ContactHu Yuehong

The First Affiliated Hospital of Xiamen University

huyuehong983@126.com+86 136 9500 9605

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026